Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 336.3% in June

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 1,511,367 shares, a growth of 336.3% from the June 15th total of 346,372 shares. Based on an average daily volume of 376,254 shares, the short-interest ratio is currently 4.0 days. Approximately 0.7% of the shares of the company are sold short.

Analyst Ratings Changes

Several analysts have recently commented on the company. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Friday, June 26th. Finally, HC Wainwright increased their price objective on Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enlivex Therapeutics has an average rating of “Hold” and a consensus price target of $247.50.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors have recently modified their holdings of ENLV. Virtu Financial LLC acquired a new stake in shares of Enlivex Therapeutics in the 4th quarter worth approximately $33,000. Invesco Ltd. purchased a new stake in Enlivex Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd boosted its position in Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after purchasing an additional 19,132 shares in the last quarter. Jane Street Group LLC grew its holdings in Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Enlivex Therapeutics in the third quarter valued at $57,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Trading Down 5.8%

ENLV stock opened at $6.28 on Tuesday. The company has a market cap of $105.76 million, a P/E ratio of -0.75 and a beta of 1.52. Enlivex Therapeutics has a 52 week low of $5.92 and a 52 week high of $31.50. The company’s 50-day moving average price is $10.04 and its 200 day moving average price is $13.15.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.